Interventions for chronic kidney disease in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Roy, Noemi B A ^a   Fortin, Patricia M ^b   Bull, Katherine R ^c   Doree, Carolyn ^b   Trivella, Marialena ^d   Hopewell, Sally ^d   Estcourt, Lise J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYUREA;

ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; GOLD STANDARD; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; SICKLE CELL ANEMIA; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84990068652     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012380     Document Type: Article

References (80)

1. Adam S, Jonassaint J, Kruger H, Kail M, Orringer EP, Eckman JR, et al. Surgical and obstetric outcomes in adults with sickle cell disease. American Journal of Medicine 2008;121(10):916-21.
2. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin C T, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118(1):19-27.
3. Alvarez O, Montane B, Lopez G, Wilkinson J, Miller T. Early blood transfusions protect against microalbuminuria in children with sickle cell disease. Pediatric Blood & Cancer 2006;47:71-6.
4. Alvarez O, Miller ST, Wang WC, Luo Z, McCarville MB, Schwartz GJ, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatric Blood & Cancer 2012;59(4):668-74.
5. Arlet JB, Ribeil JA, Chatellier G, Eladari D, De Seigneux S, Souberbielle JC, et al. Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study. BMC Nephrology 2012;13:83.
6. Asnani MR, Lynch O, Reid ME. Determining glomerular filtration rate in Homozygous sickle cell disease: Utility of serum creatinine based estimating equations. PLoS ONE 2013;8(7):e69922.
7. Asnani MR, Reid ME. Renal function in adult Jamaicans with homozygous sickle cell disease. Hematology 2015;20(7):422-8.
8. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International 2011; Vol. 79, issue 12:1331-40.
9. Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. American Journal of Hematology 2014;89:907-14.
10. Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. American Journal of Hematology 2013;88(2):116-9.
11. Botev R, Mallié JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JFM, et al. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clinical Journal of the American Society of Nephrology 2009;4(5):899-906.
12. Boyle SM, Jacobs B, Sayani FA, Hoffman B. Management of the dialysis patient with sickle cell disease. Seminars in Dialysis 2016;29(1):62-70.
13. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea down regulates endothelin-1 gene expression and up regulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics Journal 2003;3(4):215-26.
14. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New England Journal of Medicine 1995;332(20):1317-22.
15. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology / the Education Program of the American Society of Hematology 2013;2013(1):439-46.
16. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Whesthoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122(6):1062-71.
17. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?. Kidney International, Supplement 2004;92:S2-6.
18. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
19. Field JJ, Nathan DG. Advances in sickle cell therapies in the hydroxyurea era. Molecular Medicine 2014;20 Suppl 1:S37-42.
20. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. Journal of Clinical Investigation 2007;117(4):850-8.
21. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrology, Dialysis, Transplantation 1995;10(11):1963-74.
22. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. American Journal of Kidney Diseases 2006;47(1):1-7.
23. Gosmanova EO, Zaidi S, Wan JY, Adams-Graves PE. Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease. Journal of Investigative Medicine 2014;62(5):804-7.
24. Gravitz L, Pincock S. Sickle-cell disease. Nature 2014;515(7526):S1.
25. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6 Suppl 4):S398-405.
26. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Blood Cancer 2013;60(9):1482-86.
27. Haymann JP, Stankovic K, Levy P, Avellino V, Tharaux PL, Letavernier E, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clinical Journal of the American Society of Nephrology 2010;5(5):756-61.
28. Hebbel RP. Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematology/oncology clinics of North America 2014;28(2):181-98.
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
30. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. British Journal of Haematology 2000;109(2):322-7.
34. Howard J, Hart N, Roberts-Harewood M, Cummins M, Awogbade M, Davis B. Guideline on the management of acute chest syndrome in sickle cell disease. British Journal of Haematology 2015;169(4):492-505.
35. Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 2006;81(7):503-10.
36. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279-85.
37. National Kidney Foundation. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements 2013; Vol. 3, issue 1:1-163.
38. Lebensburger J, Johnson SM, Askenazi DJ, Rozario NL, Howard TH, Hilliard LM. Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia. American Journal of Hematology 2011;86(5):430-2.
39. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
40. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. Journal of the American Society of Nephrology 1999;10(11):2426-39.
41. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009;150(9):604-612.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine 1993;329(20):1456-62.
43. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, et al. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular tTarget for renoprotective iIntervention. American Journal of Pathology 2006;168(4):1073-85.
44. Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Archives of Internal Medicine 1995;155(10):1073-80.
45. Marsenic O, Couloures KG, Wiley JM. Proteinuria in children with sickle cell disease. Nephrology, Dialysis, Transplantation 2008;23(2):715-20.
46. McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. Journal of Pediatric Hematology/Oncology 2007;29(3):140-4.
47. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-Analyses:The PRISMA Statement. Annals of Internal Medicine 2009;151(4):264-9.
48. Nasr SH, Markowitz GS, Sentman RL, D'Agati VD. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney International 2006;69(7):1276-80.
49. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nature Reviews. Nephrology 2015;11(3):161-71.
50. (NICE) National Institute for Health and Care Excellence. Sickle cell disease. http://cks.nice.org.uk/sickle-cell-disease#!backgroundsub:3. London: NICE, (accessed 15 August 2016).
51. Okafor UH, Aneke E. Outcome and challenges of kidney transplant in patients with sickle cell disease. Journal of Transplantation 2013;2013:614610.
52. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
53. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2012;381(9861):142-51.
54. Pleasants S. Epidemiology: a moving target. Nature 2014;515(7526):S2-3.
55. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447-56.
56. Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. American Journal of Physiology. Lung Cellular and Molecular Physiology 2015;308(4):L314-24.
57. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 2005;84(6):363-76.
58. Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology 2015;8(5):669-79.
59. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376(9757):2018-31.
60. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
61. Rumaney MB, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Kengne AP, Ngogang J, et al. The co-inheritance of alpha-thalassemia and sickle cell anemia Is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE 2014;9:e100516.
62. Sandhu MK, Cohen A. Aging in sickle cell disease: co-morbidities and new issues in management. Hemoglobin 2015;39(4):221-4.
63. Sasongko TH, Nagalla S, Ballas SK. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD009191.pub3]
64. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. American Journal of the Medical Sciences 2010;339(3):266-9.
65. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
66. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
67. Sharpe CC, Thein SL. How I treat renal complications in sickle cell disease. Blood 2014;123(24):3720-6.
68. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology 2013;162(1):3-14.
69. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American Journal of Hematology 2012;87(8):795-803.
70. Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
71. Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89(7):2554-9.
72. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(16):16 p..
73. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2(2):109-13.
74. van der Meer IM, Cravedi P, Remuzzi G. The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis & Tissue Repair 2010;3(7):11 p..
75. Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardon MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. American Journal of Cardiology 1985;55(8):1023-6.
76. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663-72.
77. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012;120(3):528-37.
78. McPherson Yee M, Jabbar SF, Osunkwo I, Clement L, Lane PA, Eckman JR, et al. Chronic kidney disease and albuminuria in children with sickle cell disease. Clinical Journal of The American Society of Nephrology 2011;6(11):2628-33.
79. Zafrani L, Ince C. Microcirculation in acute and chronic kidney diseases. American Journal of Kidney Diseases 2015;66(6):1083-94.
80. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Current Diabetes Reviews 2008;4(1):39-45.